PAG
SPRY icon

Private Advisor Group’s ARS Pharmaceuticals SPRY Stock Holding History

Private Advisor Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Sell
26,092
-4,150
-14% -$35.7K ﹤0.01% 2340
2026
Q1 		$243K Sell
30,242
-1,218
-4% -$11.7K ﹤0.01% 2340
2025
Q4 		$367K Buy
31,460
+10,878
+53% +$106K ﹤0.01% 2023
2025
Q3 		$207K Buy
+20,582
New +$295K ﹤0.01% 2313

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Private Advisor Group's SPRY Position: Q2 2026 in Review

Private Advisor Group reduced its ARS Pharmaceuticals (SPRY) stake by 14% in Q2 2026, selling an estimated $35.7K and leaving 26,092 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Private Advisor Group first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $367K in Q4 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Private Advisor Group held 26,092 shares of ARS Pharmaceuticals worth $209K as of Q2 2026.
  • Private Advisor Group sold 4,150 ARS Pharmaceuticals shares in Q2 2026, an estimated $35.7K.
  • ARS Pharmaceuticals made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2340 holding.
  • Private Advisor Group first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Private Advisor Group's ARS Pharmaceuticals position peaked at $367K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.